DUBLIN, Ireland and TREVOSE, Pa., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that management will be presenting at the 26th Annual Oppenheimer Healthcare Conference to be held December 8 – 9, 2015 in New York City.
Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, is scheduled to present on Tuesday, December 8, 2015 at 1:35 p.m. EST. The presentation will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma’s strategic focus is to build a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. Strongbridge Biopharma’s lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing’s syndrome. COR-003 and COR-005 have received orphan designation from both the European Medicines Agency and the U.S. Food and Drug Administration, and the Company is pursuing orphan designation for COR-004. Strongbridge Biopharma recently expanded its rare endocrine disease franchise with the completion of transactions for two Phase 2 product candidates: COR-004, a novel second-generation antisense compound, which is in clinical development for the treatment of acromegaly and designed to block the synthesis of growth hormone receptor (GHr), thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile, being investigated for the treatment of acromegaly, with potential additional applications in Cushing’s disease and neuroendocrine tumors. Strongbridge Biopharma’s intent is to independently commercialize its rare endocrine assets in key global markets.
CONTACT: Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 lrocco@elixirhealthpr.com Investor Relations ICR Inc. Stephanie Carrington +1 646-277-1282 Stephanie.Carrington@icrinc.com USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
